- Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43% YOY.
- Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands their customers, solves their pain points, and has earned their trust. This is a deep moat.
- The legacy compounded pharmaceutical products business finally has the scale to be highly profitable, and would earn ~$1 a share as a stand alone enterprise.
- Harrow's aggressive and capable management is launching a huge expansion into higher margin branded pharmaceutical products, guiding to doubling the company by 2024. $2 EPS will result, then grow rapidly.
- The new product launch means expenses today to generate earnings in the future. The market is missing the opportunity and is focused only on the reduced earnings today.
For further details see:
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch